Evolution Global Acquisition Corp (EVOX) is a Cayman Islands blank check company (SPAC) that completed its IPO on November 12, 2025, raising $240M gross proceeds. This is the first quarterly 10-Q filing (period ending March 31, 2026) following the inaugural annual 10-K. Under a liquidation lens, the recovery posture is structurally constrained by the SPAC's grantor trust architecture: virtually all economic assets are held in trust and legally ring-fenced for Class A public shareholders at redemption value, leaving residual recovery to equity holders of the permanent capital structure deeply negative. Total assets of $244.5M consist almost entirely of $243.3M in investments held in Trust Account (U.S. Treasury funds, Level 1), $1.0M cash outside trust, $140K current prepaid, and $44K long-term prepaid insurance. Applying liquidation haircuts: Trust Account assets receive effectively 100% recovery under the lens (U.S. Treasuries, liquid), cash at 100%, prepaids at 0% (no realizable value on wind-up). Gross liquidation asset recovery approximates $244.3M. Against this, total liabilities at face value are $9.9M, of which $9.6M is the deferred underwriting fee — a contingent liability that under the trust indenture waiver is only payable upon a successful Business Combination. If the company liquidates without a deal, the underwriters have contractually agreed to waive this fee, meaning the $9.6M deferred underwriting fee would not be an actual liquidation claim. However, under the liquidation lens as defined, liabilities are held at face value, so the analysis treats it as a $9.6M obligation. Current liabilities of $263K (accounts payable $145K, due to sponsor $20K, accrued offering costs $98K) are face-value obligations. The $243.3M trust balance is fully offset by temporary equity (Class A shares subject to possible redemption at $10.14/share) — this is not available to permanent equity. Net recovery to permanent equity (Class B shareholders/founder shares) equals total assets minus total liabilities minus temporary equity: $244.5M - $9.9M - $243.3M = negative $8.7M, exactly matching the reported shareholders' deficit of ($8.67M). No improvement from the December 31, 2025 position (deficit was ($8.50M)); the deficit widened by $169K in Q1 2026 from operating costs, with trust interest accruing entirely to temporary equity via accretion. Cash outside trust declined modestly from $1.12M to $1.01M. No working capital loans outstanding. The deferred underwriting fee ($9.6M) is disclosed in MD&A but the waiver-upon-liquidation contingency is discussed in narrative without a separate XBRL tag for the contingent nature of the obligation.
▼ Community Notes